IDDS Adds Respected Business Development Vice President to Management Team.

NEW YORK -- Innovative Drug Delivery Systems (OTC BB: ITRD), a developer of novel pain relief treatments, named Michael Sheckler as Vice President for Business Development. Mr. Sheckler brings nearly 20 years of pharmaceutical marketing experience to IDDS. He began his career with the Ross Division of Abbott Laboratories, selling nutritional and pharmaceutical products. During his time there, he served in a variety of sales roles, winning numerous sales awards. As a market research analyst, Mr. Sheckler was responsible for the market assessment and product launch plans for several line extensions.

Mr. Sheckler left Ross in 1999 to join Bespak, Inc., a drug delivery technology company, as Marketing Manager. He also held the positions of Director of Marketing and Product Management and Head of Marketing for the Nasal Drug Delivery business stream. In the latter role, he was instrumental in launching the business stream, assessing and growing new business opportunities in the U.S., and developing and implementing the launch and marketing plans for new products. Prior to joining IDDS, Inc., Mr. Sheckler worked with Intranasal Technology, Inc., a Kentucky-based nasal drug delivery company as Director of Business Development.

Mr Sheckler graduated from Indiana University and obtained his MBA from The Fuqua School of Business at Duke University in Durham, North Carolina. He is an Editorial Advisor for the journal, "Specialty Pharma", and is Chairperson of this year's Pharmaceutical Education Associates' conference on Nasal Drug Delivery, July 25-27 in Washington, D.C.

Dr. Daniel Carr, Chief Medical Officer, commented, "Michael's business development acumen is a welcome addition to the IDDS management team. His wealth of experience in sales, marketing, and business development as well as the relationships he has developed over the years will ensure that IDDS partners with industry leaders to bring its novel therapeutics to patients worldwide."

The role of Vice President for Business Development within IDDS is to maintain and build our partnerships with existing stakeholders and to forge new relationships with companies capable of marketing our product candidates. IDDS is currently seeking distribution partners with the resources and reach to market the company's late stage product candidates.

"The passion to bring innovative pain relief to patients is one that I individually, and IDDS as a company, share," said Mr. Sheckler. "Our partners and distributors likewise share this sense of urgency. By developing and commercializing differentiated pain relief products, IDDS provides the flexibility and versatility the medical community is looking for to overcome limitations of current pain medications."

About IDDS

IDDS is a specialty pharmaceutical company with a late stage development pipeline of prescription pain medications that address unmet and underserved medical needs for treatment of moderate-to-severe pain.

Utilizing proprietary technologies, the Company minimizes development risk and maximizes commercial opportunity through novel administration routes and broader labeling for existing FDA-approved drugs. Its simple, safe, cost-effective solutions to complex analgesic problems leverage the healthcare industry's growing awareness that pain management is a vital component in patient care and recovery.

For more information, visit www.idds.com.

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement.